Document is current
Any future updates will be listed below
-
Authors
Sleiman, Joseph
Brand, Rhonda M.
Pai, Reetesh
Brand, Randall E.
Rhee, John
Schwartz, Marc
Davar, Diwakar https://orcid.org/0000-0002-7846-8055
- License Information
-
More Information
Article History
Received: 15 May 2023
Accepted: 25 June 2023
First Online: 15 July 2023
Declarations
:
: J.S., R.M. B, R.E.B, J.R and M.S. have no conflict of interest to disclose. R. P. has the following disclosures: Consultant for Alimentiv. D.D. has the following disclosures: Grants/Research Support (institutional): Arcus, CellSight Technologies, Immunocore, Merck, Regeneron Pharmaceuticals Inc., Tesaro/GSK. Consultant: Clinical Care Options (CCO), Finch Therapeutics, Gerson Lehrman Group (GLG), Medical Learning Group (MLG), Xilio Therapeutics. CE Speakers’ Bureau: Castle Biosciences. Stockholder: None. Intellectual Property: US Patent 63/124,231, “Compositions and Methods for Treating Cancer”, Dec 11, 2020 US Patent 63/208,719, “Compositions and Methods For Determining Responsiveness to Immune Checkpoint Inhibitors (ICI), Increasing Effectiveness of ICI and Treating Cancer”, June 9, 2021.
: The patient has consented through the University of Pittsburgh IRB protocol CR20010266-005.
